NorthWest Biotherapeutics Inc (NWBO)

[photonic5]

My personal hypothesis is that the full range of stem cell antigens from the tumor are needed to generate an immune response using DCVax. If all the stem cell antigens are present in the tumor sample provided, the patient responds. If not, the immune response will not be complete.

I think that is why only 8% of those patients with historically favorable factors like age, MGMT status, and complete tumor resection responded to DCVax. GBM is quite heterogeneous and extends into normal tissue in microscopic fashion. Capturing the full range of antigens from the stem cells may be the challenge here. I'm excited to see where further research takes these challenges. Identifying malignant vs. normal tissues on a cellular basis will continue be a challenge and may complement the targeting with this therapy. Identifying growth centers is key to identifying stem cells. While there is work to do in this area, I'm confident we are at the forefront of a therapy breakthrough here.

The side effects are what make this therapy truly exciting. No side effects. None. Worst side effect from this therapy is cost. That will be managed with manufacturing efficiency gains.